(1) Recognize the germline mutations associated with pheochromocytoma and paraganglioma and describe the pheochromocytoma/paraganglioma-specific screening recommendations for individuals with confirmed germline hereditary syndromes. (2) Compare and contrast the primary treatment options for individuals with pheochromocytoma and paraganglioma. (3) Evaluate the emerging data for the treatment of advanced pheochromocytoma and paraganglioma.
- Provider:National Comprehensive Cancer Network
- Activity Link: https://education.nccn.org/node/95270
- Start Date: 2024-05-17 05:00:00
- End Date: 2024-05-17 05:00:00
- Credit Details: AAPA Category 1 Credit™️: 1.0 hours
AMA PRA Category 1 Credit™️: 1.0 hours
Nursing: 1.0 hours
Pharmacy: 1.0 hours - Commercial Support: Source: AstraZeneca (Any division) - Amount: 0.0 - Is Kind Support: False Source: Exelixis - Amount: 0.0 - Is Kind Support: False Source: GlaxoSmithKline - Amount: 0.0 - Is Kind Support: False Source: Lantheus - Amount: 0.0 - Is Kind Support: False Source: Merck (Any division) - Amount: 0.0 - Is Kind Support: False Source: Novartis Corporation Pharmaceuticals - Amount: 0.0 - Is Kind Support: False
- Activity Type: Enduring Material
- CME Finder Type: Online Learning
- Fee to Participate: No, it's free
- Measured Outcome: Learner Knowledge, Learner/Team Competence, Learner/Team Performance
- Provider Ship: Directly Provided
- Registration: Open to all
Subscribe
Login
0 Comments
Oldest